Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604087 | 0.82 | HRH4 (0.62) | HRH4 | |
| SCHEMBL4875265 | 0.80 | CYP2C19 (0.43) | HRH4 | |
| SCHEMBL4877385 | 0.75 | HRH4 (0.62) | HRH4NPY5RACHE | |
| SCHEMBL2091407 | 0.73 | RXRA (0.48) | RXRARXRBRXRG | |
| SCHEMBL2167222 | 0.70 | HRH4 (0.57) | HRH4NPY5RACHE | |
| SCHEMBL4868863 | 0.70 | HRH4 (0.42) | HRH4DHFRFBP1ACHE | |
| SCHEMBL4876581 | 0.68 | HRH4 (0.54) | HRH4ACHE | |
| SCHEMBL4875322 | 0.66 | ACHE (0.36) | ACHESYK | |
| SCHEMBL12256594 | 0.65 | CYP19A1 (0.33) | ACHE | |
| SCHEMBL4869436 | 0.64 | TYMS (0.39) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | HRH4 3013/4885TACR3 4612/4885NPY5R 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.